Praxis Precision Medicines to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 19, 2026, and Participate in Upcoming Investor Conferences
Rhea-AI Summary
Praxis Precision Medicines (NASDAQ: PRAX) will report fourth quarter and full year 2025 financial results and provide a corporate update before markets open on February 19, 2026 at 8:00 am ET. The company will host a conference call and live webcast; replays will be available on the Events & Presentations page for ~90 days.
Management will present at Guggenheim Biotech Summit on Feb 11, 2026 and TD Cowen Health Care Conference on Mar 2, 2026, with live webcasts and subsequent replays.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
Key biotech peers like AVXL, NKTR and SANA showed positive moves (e.g., AVXL +6.48%, NKTR +4.63%, SANA +6.5%), but the momentum scanner flagged no coordinated sector momentum, suggesting PRAX’s move was more stock-specific than part of a broad sector rotation.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 04 | Inducement grants | Neutral | +0.8% | New employee inducement RSU awards under 2024 Inducement Plan. |
| Jan 13 | Leadership appointment | Positive | +1.9% | Appointment of global epilepsy leader as Head of Clinical Strategy. |
| Jan 12 | Strategic update | Positive | -4.4% | Pivotal 2025 recap, 2026 priorities, NDAs and large capital raise. |
| Jan 09 | Inducement grants | Neutral | -4.4% | Small RSU awards to new hires under Nasdaq inducement rules. |
| Jan 08 | Board/executive changes | Positive | -2.0% | New directors and senior promotions to support late-stage growth. |
Recent strategically positive updates sometimes saw negative next-day reactions, while routine items like inducement grants drew modest or mixed moves.
Over the past month, Praxis reported governance and strategic updates, including board and executive appointments on Jan 8, 2026 and a forward-looking pipeline and financing update on Jan 12, 2026. It also issued several inducement grant announcements in early January and February. These events produced both positive and negative one-day moves, with notably negative reactions following some strategically positive updates. Today’s announcement adds an earnings date and conference visibility on top of that backdrop of late‑stage pipeline positioning and recent capital-raising activity.
Market Pulse Summary
This announcement sets expectations for Praxis’s upcoming fourth quarter and full-year 2025 financial results on February 19, 2026 and highlights additional visibility through two investor conferences. In the weeks prior, the company detailed late-stage pipeline plans, strengthened its leadership team, and reported capital-raising progress. Investors may focus on how the forthcoming earnings and corporate update refine views on cash position, late-stage programs, and execution timelines laid out in earlier releases.
AI-generated analysis. Not financial advice.
BOSTON, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced it will report its financial results for the fourth quarter and full year ended December 31, 2025, and provide a corporate update before the financial markets open on Thursday, February 19, 2026.
The Company will host a conference call and a live webcast to review the fourth quarter financial results and provide a corporate update on Thursday, February 19, 2026, at 8:00 am ET, which can be accessed by visiting this registration link. The live webcast will also be available on the Events & Presentations page of the Investors + Media section of the company’s website www.praxismedicines.com.
Praxis management will also be present at the following two upcoming investor conferences:
- Guggenheim Emerging Outlook: Biotech Summit 2026: a corporate presentation will take place on February 11 at 1pm ET at the Lotte New York Palace Hotel in New York City, NY. A live webcast will be available through link.
- TD Cowen 46th Annual Health Care Conference: a corporate presentation will take place on March 2 at 11:50am ET at the Boston Marriott Copley Place Hotel in Boston, MA. A live webcast will be available through link.
Replays will be available on Praxis’ Events & Presentations page of the company’s website after each event for approximately 90 days.
About Praxis
Praxis Precision Medicines is a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across movement disorders and epilepsy, with four late-stage product candidates. For more information, please visit www.praxismedicines.com and follow us on Facebook, Instagram, LinkedIn and Twitter/X.
Investor Contact: Praxis Precision Medicines investors@praxismedicines.com 857-702-9452 Media Contact: Dan Ferry LifeSci Advisors Daniel@lifesciadvisors.com 617-430-7576
FAQ
When will Praxis (PRAX) report Q4 and full year 2025 financial results?
How can investors access the Praxis (PRAX) February 19, 2026 webcast and call?
Which investor conferences will Praxis (PRAX) attend in February–March 2026?
What time is the Praxis (PRAX) presentation at the Guggenheim Biotech Summit on Feb 11, 2026?
When is the Praxis (PRAX) presentation at the TD Cowen Health Care Conference on March 2, 2026?
Will Praxis (PRAX) provide replays of the February and March 2026 presentations?
